ReviewJournal of clinical medicine2026

Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance.

Christos Damaskos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.